Company Description

Salspera is focused on the development and commercialization of a new class of immunotherapeutics for the treatment of solid tumors.

This new class of drugs, sometimes referred to as “live biopharmaceuticals” are genetically modified biological agents which have the capability of expressing select anti-tumoral agents within the tumor’s microenvironment.

Our lead program, Saltikva, is an attenuated strain of Salmonella Typhimurium that is non-toxic and orally administered.

Saltikva is being developed for the treatment of multiple oncology indications, including pancreatic cancer and osteosarcoma.

Our Company is entering into pivotal Phase 3 clinical trials for our Saltikva product in the treatment of Stage IV metastatic pancreatic cancer patients.

Salspera Inc.

Country	United States
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	2
CEO	Eddie Moradian, PhD

Contact Details

Address: 45 Prospect Street Cambridge, MA 02139 United States
Phone	(652) 402-5587
Website	salspera.com

Stock Details

Ticker Symbol	TKVA
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0002084032
Employer ID	87-4698872
SIC Code	2834

Key Executives

Name	Position
Eddie Moradian	Executive Chairman, Chief Executive Officer, Chief Financial Officer and Director
Daniel Saltzman, MD	Chief Medical Officer and Director
Brent Lonson	Chief Financial Officer
Charles Garner	Director
Luisa Ingargiola	Director
David Schaffer, PhD	Director

Latest SEC Filings

Date	Type	Title
Mar 4, 2026	FWP	Free Writing Prospectus
Feb 23, 2026	S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
Feb 2, 2026	S-1	General form for registration of securities under the Securities Act of 1933
Dec 29, 2025	DRS/A	[Amend] [Cover] Draft Registration Statement
Sep 12, 2025	DRS	[Cover] Draft Registration Statement

View All SEC Filings